Disodium cromoglycate in ragweed-allergic rhinitis

Knight, Allan; Underdown, Brian J.; Demanuele, F.; Hargreave, Frederick E.

doi:10.1016/0091-6749(76)90132-9

Cited by 13 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…431,432 Intranasal administration of cromolyn sodium, compared with placebo, improves symptoms of SAR. [433][434][435] In PAR, with marked skin test responses, 436 benefit has been found in some but not all studies of patients with PAR. 437 Intranasal cromolyn may reduce nasal eosinophils in patients with AR.…”

Section: Intranasal Cromolynmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

229

189

View full text Add to dashboard Cite

Section: Intranasal Cromolynmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

229

189

View full text Add to dashboard Cite

“…DSCG has been shown to be more effective than placebo in patients with seasonal AR in controlling nasal symptoms of sneezing, rhinorrhea, and nasal congestion as treatment during their peak allergy season 2025–2029 . The largest double‐blind placebo‐controlled trial included 1150 patients with seasonal AR treated for 2 weeks (580 patients on DSCG, 570 treated with placebo) 2025 .…”

Section: Managementmentioning

confidence: 99%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

153

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

“…Standard forms of drug therapy have included antihistamines, either alone or in combination with decongestant agents of the sympathomimetic group, vasoconstrictor nasal sprays and disodium cromoglycate taken intranasally as a powder or solution (Knight et al, 1976;Posey & Nelson, 1977).…”

Section: Introductionmentioning

confidence: 99%

Immunological parameters in perennial rhinitis

Knight

Underdown

Connell

et al. 1979

Clin Experimental Allergy

View full text Add to dashboard Cite

As part of a study of the effectiveness of beclomethasone dipropionate in perennial rhinitis five immunologically related parameters were measured. These included skin tests, total IgE, specific IgE, nasal and peripheral blood eosinophil counts. In addition, nasal biopsies were obtained in twenty out of sixty patients.It was apparent that patients with perennial rhinitis formed a heterogeneous group who could be divided into three groups based on the extent of immunological abnormality detected. Group 1 consisted of twenty patients who displayed no abnormality in any of the five parameters studied. Group 2 consisted of twenty-six patients in whom specific IgE was not detected but who had varying degrees of abnormal findings in the other laboratory parameters. The remaining fourteen patients formed a third group in whom specific IgE was detected in addition to abnormalities in other parameters.In general, patients with detectable specific IgE had a higher frequency of abnormal parameters, including abnormal histology of their nasal biopsy, than patients in whom no specific IgE was detected. The heterogeneous nature of perennial rhinitis is discussed. Despite the heterogeneous nature ofthe total patient group, the majority of patients (80%) treated with beclomethasone dipropionate improved compared to 20% improved in the placebo group. There was no difference in the drug effect between the three groups of patients.

show abstract

Disodium cromoglycate in ragweed-allergic rhinitis

Cited by 13 publications

References 9 publications

Rhinitis 2020: A practice parameter update

Rhinitis 2020: A practice parameter update

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Immunological parameters in perennial rhinitis

Contact Info

Product

Resources

About